XML 31 R11.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenue Recognition | 9 Months Ended
--- | ---
Sep. 26, 2020
Revenue from Contract with Customer [Abstract] |
Revenue Recognition | REVENUE RECOGNITION Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products. Disaggregation of Revenue We generated net sales in the following geographic locations(1) (in millions):
| Three Months Ended |  | Nine Months Ended
| September 26, 2020 |  | September 28, 2019 |  | September 26, 2020 |  | September 28, 2019
U.S. | $ | 820.8 |  |  | $ | 785.9 |  |  | $ | 2,571.1 |  |  | $ | 2,323.2 |
Europe(2) | 326.6 |  |  | 334.6 |  |  | 1,011.0 |  |  | 991.3 |
All other countries(3) | 66.3 |  |  | 70.6 |  |  | 191.7 |  |  | 200.1 |
Total net sales | $ | 1,213.7 |  |  | $ | 1,191.1 |  |  | $ | 3,773.8 |  |  | $ | 3,514.6 |
(1) Derived from the location of the entity that sells to a third party. (2) Includes Ireland net sales of $10.8 million and $22.3 million for the three and nine months ended September 26, 2020, respectively, and $5.2 million and $17.3 million for the three and nine months ended September 28, 2019, respectively. (3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada. Product Category We re-aligned our product categories in our CSCA and CSCI segments as of December 31, 2019. The re-alignment standardizes our categories and product level detail to provide consistency. This transformative step will optimize the way in which management reports and evaluates our business. The following is a summary of our net sales by category (in millions); the comparative periods reflect the product category re-alignment:
| Three Months Ended |  | Nine Months Ended
| September 26, 2020 |  | September 28, 2019 |  | September 26, 2020 |  | September 28, 2019
CSCA(1) |  |  |  |  |  |  |
Upper respiratory | $ | 114.2 |  |  | $ | 123.4 |  |  | $ | 385.5 |  |  | $ | 377.4 |
Digestive health | 107.1 |  |  | 85.0 |  |  | 326.1 |  |  | 293.6 |
Pain and sleep-aids | 100.6 |  |  | 89.4 |  |  | 318.7 |  |  | 272.0 |
Nutrition | 100.1 |  |  | 97.1 |  |  | 290.9 |  |  | 282.6 |
Healthy lifestyle | 86.1 |  |  | 87.9 |  |  | 253.4 |  |  | 250.0 |
Oral self-care | 81.1 |  |  | 54.2 |  |  | 199.6 |  |  | 54.2 |
Skincare and personal hygiene | 49.2 |  |  | 45.4 |  |  | 138.8 |  |  | 136.7 |
Vitamins, minerals, and supplements | 6.3 |  |  | 6.2 |  |  | 19.1 |  |  | 18.7 |
Animal health | — |  |  | 1.8 |  |  | — |  |  | 43.7 |
Other CSCA(2) | 19.3 |  |  | 22.9 |  |  | 60.1 |  |  | 48.3 |
Total CSCA | 664.0 |  |  | 613.3 |  |  | 1,992.2 |  |  | 1,777.2 |
CSCI |  |  |  |  |  |  |
Skincare and personal hygiene | 83.1 |  |  | 88.9 |  |  | 275.4 |  |  | 296.5 |
Upper respiratory | 62.3 |  |  | 72.1 |  |  | 191.9 |  |  | 193.9 |
Vitamins, minerals, and supplements | 52.9 |  |  | 46.2 |  |  | 139.9 |  |  | 133.1 |
Pain and sleep-aids | 49.0 |  |  | 40.5 |  |  | 136.0 |  |  | 120.3 |
Healthy lifestyle | 40.6 |  |  | 38.2 |  |  | 124.7 |  |  | 134.2 |
Oral self-care | 25.2 |  |  | 24.3 |  |  | 68.8 |  |  | 27.7 |
Digestive health | 6.8 |  |  | 5.3 |  |  | 17.9 |  |  | 19.3 |
Other CSCI(3) | 19.1 |  |  | 32.0 |  |  | 88.2 |  |  | 100.8 |
Total CSCI | 339.0 |  |  | 347.5 |  |  | 1,042.8 |  |  | 1,025.8 |
RX | 210.7 |  |  | 230.3 |  |  | 738.8 |  |  | 711.6 |
Total net sales | $ | 1,213.7 |  |  | $ | 1,191.1 |  |  | $ | 3,773.8 |  |  | $ | 3,514.6 |
(1) Includes net sales from our OTC contract manufacturing business.
(2) | Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3) | Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $76.7 million and $190.7 million for the three and nine months ended September 26, 2020, respectively, and $73.9 million and $207.0 million for the three and nine months ended September 28, 2019, respectively. We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery. Contract Balances The following table provides information about contract assets from contracts with customers (in millions):
| Balance Sheet Location |  | September 26, 2020 |  | December 31, 2019
Short-term contract assets | Prepaid expenses and other current assets |  | $ | 21.2 |  |  | $ | 26.3 |

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration